Arcellx, Inc. (NASDAQ:ACLX – Get Free Report) Director Olivia C. Ware sold 9,402 shares of the stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $55.55, for a total transaction of $522,281.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Olivia C. Ware also recently made the following trade(s):
- On Friday, March 15th, Olivia C. Ware sold 9,000 shares of Arcellx stock. The shares were sold at an average price of $70.40, for a total value of $633,600.00.
Arcellx Trading Up 1.8 %
Shares of NASDAQ:ACLX opened at $54.50 on Friday. Arcellx, Inc. has a 52 week low of $30.74 and a 52 week high of $75.10. The company’s 50 day moving average is $65.23 and its two-hundred day moving average is $54.84. The company has a market cap of $2.90 billion, a PE ratio of -37.07 and a beta of 0.02.
Institutional Investors Weigh In On Arcellx
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Citigroup Inc. purchased a new position in Arcellx in the first quarter valued at approximately $26,000. China Universal Asset Management Co. Ltd. lifted its position in Arcellx by 98.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,248 shares of the company’s stock valued at $45,000 after acquiring an additional 619 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Arcellx by 219.0% in the first quarter. Tower Research Capital LLC TRC now owns 1,464 shares of the company’s stock valued at $45,000 after acquiring an additional 1,005 shares in the last quarter. California State Teachers Retirement System purchased a new position in shares of Arcellx during the first quarter worth about $54,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Arcellx during the first quarter worth about $60,000. Institutional investors and hedge funds own 96.03% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on ACLX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $81.00 price objective on shares of Arcellx in a research note on Thursday, April 11th. Truist Financial lifted their target price on Arcellx from $57.00 to $87.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. Scotiabank reissued an “outperform” rating and set a $82.00 price target on shares of Arcellx in a research report on Thursday, April 4th. Canaccord Genuity Group lifted their price objective on shares of Arcellx from $66.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, February 29th. Finally, Barclays increased their target price on shares of Arcellx from $62.00 to $73.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $74.17.
View Our Latest Analysis on ACLX
Arcellx Company Profile
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
Featured Stories
- Five stocks we like better than Arcellx
- What is Insider Trading? What You Can Learn from Insider Trading
- Comprehensive PepsiCo Stock Analysis
- ETF Screener: Uses and Step-by-Step Guide
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- How Investors Can Find the Best Cheap Dividend Stocks
- Bear Market Funds to Watch This Year
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.